Hospital, Southport, UK; Olanrewaju Sorinola, South Warwickshire NHS Foundation Trust, Warwick, UK; Sarah Stock, Co-Investigator, Royal Infirmary of Edinburgh, Edinburgh, UK; Andrew Tapp, Royal Shrewsbury Hospital, Shrewsbury, UK; Myles Taylor, Royal Devon & Exeter Hospitals NHS Trust, Exeter, UK; Tg Teoh, St Mary's Hospital, London (with Imperial), London, UK; Vasso Terzidou, Chelsea & Westminster Hospital, London, UK; Basky Thilaganathan, St George's Hospital, University of London, London, UK; Jim Thornton, Nottingham City Hospital/ Queen's Medical Centre, Nottingham, UK; A. John Tomlinson, Royal Bolton Hospital, Bolton, UK; Clare Tower, Manchester Academic Science Centre, Manchester, UK; Derek Tuffnell, Bradford Royal Infirmary, Bradford, UK; Graham Tydeman, Forth Park Hospital, Kirkcaldy, Fife, UK; Patrick Vandekerckhove, St Mary's Hospital, Newport - Isle of Wight, UK; Karen Watkins, Royal Cornwall Hospital, Truro, UK; Ross Welch, Derriford Hospital, Plymouth, UK; Ulla-Britt Wennerholm, Sahlgrenska University Hospital, Gothenburg, Sweden. Background Progesterone administration has been shown to reduce the risk of preterm birth and neonatal morbidity in women at high risk, but there is uncertainty about longer term effects on the child. Methods We conducted a double blind randomised placebo controlled trial of vaginal progesterone, 200mg daily taken from 22-24 to 34 weeks of gestation, on pregnancy and infant outcomes in women at risk of preterm birth (because of previous spontaneous birth at weeks of gestation, or a cervical length or because of a positive fetal ≤34+0 ≤25mm,
Hospital, Southport, UK; Olanrewaju Sorinola, South Warwickshire NHS Foundation Trust, Warwick, UK; Sarah Stock, Co-Investigator, Royal Infirmary of Edinburgh, Edinburgh, UK; Andrew Tapp, Royal Shrewsbury Hospital, Shrewsbury, UK; Myles Taylor, Royal Devon & Exeter Hospitals NHS Trust, Exeter, UK; Tg Teoh, St Mary's Hospital, London (with Imperial), London, UK; Vasso Terzidou, Chelsea & Westminster Hospital, London, UK; Basky Thilaganathan, St George's Hospital, University of London, London, UK; Jim Thornton, Nottingham City Hospital/ Queen's Medical Centre, Nottingham, UK; A. John Tomlinson, Royal Bolton Hospital, Bolton, UK; Clare Tower, Manchester Academic Science Centre, Manchester, UK; Derek Tuffnell, Bradford Royal Infirmary, Bradford, UK; Graham Tydeman, Forth Park Hospital, Kirkcaldy, Fife, UK; Patrick Vandekerckhove, St Mary's Hospital, Newport - Isle of Wight, UK; Karen Watkins, Royal Cornwall Hospital, Truro, UK; Ross Welch, Derriford Hospital, Plymouth, UK; Ulla-Britt Wennerholm, Sahlgrenska University Hospital, Gothenburg, Sweden. Background Progesterone administration has been shown to reduce the risk of preterm birth and neonatal morbidity in women at high risk, but there is uncertainty about longer term effects on the child. Methods We conducted a double blind randomised placebo controlled trial of vaginal progesterone, 200mg daily taken from 22-24 to 34 weeks of gestation, on pregnancy and infant outcomes in women at risk of preterm birth (because of previous spontaneous birth at ≤34+0 weeks of gestation, or a cervical length ≤25mm, or because of a positive fetal
Corrected_preprint_version_OPPTIMUM_clean.docx